Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;19(10):869-77.
doi: 10.1016/j.parkreldis.2013.05.013. Epub 2013 Jun 17.

Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations

Christina Sundal  1 , Shinsuke Fujioka, Jay A Van Gerpen, Christian Wider, Alexandra M Nicholson, Matt Baker, Elizabeth A Shuster, Jan Aasly, Salvatore Spina, Bernardino Ghetti, Sigrun Roeber, James Garbern, Alex Tselis, Russell H Swerdlow, Bradley B Miller, Anne Borjesson-Hanson, Ryan J Uitti, Owen A Ross, A Jon Stoessl, Rosa Rademakers, Keith A Josephs, Dennis W Dickson, Daniel Broderick, Zbigniew K Wszolek
Affiliations

Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations

Christina Sundal et al. Parkinsonism Relat Disord. 2013 Oct.

Abstract

Atypical Parkinsonism associated with white matter pathology has been described in cerebrovascular diseases, mitochondrial cytopathies, osmotic demyelinating disorders, leukoencephalopathies leukodystrophies, and others. Hereditary diffuse leukoencephalopathy with spheroids (HDLS) is an autosomal dominant disorder with symptomatic onset in midlife and death within a few years after symptom onset. Neuroimaging reveals cerebral white matter lesions that are pathologically characterized by non-inflammatory myelin loss, reactive astrocytosis, and axonal spheroids. Most cases are caused by mutations in the colony-stimulating factor 1 receptor (CSF1R) gene. We studied neuropathologically verified HDLS patients with CSF1R mutations to assess parkinsonian features. Ten families were evaluated with 16 affected individuals. During the course of the illness, all patients had at least some degree of bradykinesia. Fifteen patients had postural instability, and seven had rigidity. Two patients initially presented with parkinsonian gait and asymmetrical bradykinesia. These two patients and two others exhibited bradykinesia, rigidity, postural instability, and tremor (two with resting) early in the course of the illness. Levodopa/carbidopa therapy in these four patients provided no benefit, and the remaining 12 patients were not treated. The mean age of onset for all patients was about 45 years (range, 18-71) and the mean disease duration was approximately six years (range, 3-11). We also reviewed HDLS patients published prior to the CSF1R discovery for the presence of parkinsonian features. Out of 50 patients, 37 had gait impairments, 8 rigidity, 7 bradykinesia, and 5 resting tremor. Our report emphasizes the presence of atypical Parkinsonism in HDLS due to CSF1R mutations.

Keywords: Autosomal dominant; CSF1R mutation; HDLS; Parkinsonism; White matter disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
MRI (A-C) and neuropathology (D-F) of HDLS cases with CSF1R mutations A, B) Axial FLAIR MRI images; C) Axial T2-weighted MRI image. A) Localized, periventricular, deep, and subcortical white matter lesions (WML), more severe on the left side (arrows). B) Bilateral frontoparietal WML involving periventricular, deep, and subcortical areas with U-fiber sparing (arrows). C) Involvement of the corticospinal tracts bilaterally (arrows) at the level of the mesencephalon. D, E) Luxol fast blue; F) Hematoxylin-eosin. D) Myelin loss in the white matter of the superior frontal lobe. E) Tissue vacuolation with axonal spheroids (arrow) (magnification: ×400). F) The ventrolateral part of substantia nigra has minimal focal neuronal loss with extraneuronal neuromelanin (magnification: ×100).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Crithely M. Arteriosclerotic parkinsonism. Brain. 1929;52:23–83.
    1. Demirkiran M, Bozdemir H, Sarica Y. Vascular parkinsonism: a distinct, heterogeneous clinical entity. Acta Neurol Scand. 2001;104:63–7. - PubMed
    1. Wegner F, Strecker K, Schwarz J, Wagner A, Heinritz W, Sommerer F, et al. Vascular parkinsonism in a CADASIL case with an intact nigrostriatal dopaminergic system. J Neurol. 2007;254:1743–5. - PubMed
    1. Sibon I, Guyot M, Allard M, Tison F. Parkinsonism following anterior choroidal artery stroke. Eur J Neurol. 2004;11:283–4. - PubMed
    1. Netravathi M, Pal PK, Indira Devi B. A clinical profile of 103 patients with secondary movement disorders: correlation of etiology with phenomenology. Eur J Neurol. 2012;19:226–33. - PubMed

Publication types

MeSH terms

Substances

Supplementary concepts